The a priori characterization of distinct biological HER2+ breast cancer subgroups associated with poorer prognosis and resistance to trastuzumab-based adjuvant/neoadjuvant therapy using DNA microarrays is not currently feasible for large-scale clinical applications. This evidence concerns the gene ERBB2 and breast cancer.